Phase I study for assessment of safety of gene therapy with GX-12 in combination with HAART for the HIV-1 infected patients

Trial Profile

Phase I study for assessment of safety of gene therapy with GX-12 in combination with HAART for the HIV-1 infected patients

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Antiretrovirals; GX 12
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors Genexine
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Jun 2013 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently' (last verified May 2008).
    • 11 May 2008 The expected completion date for this trial is now 1 Dec 2009 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top